TY  - JOUR
AU  - Alonso, S
AU  - Riveiro-Barciela, M
AU  - Fernandez, I
AU  - Rincón, D
AU  - Real, Y
AU  - Llerena, S
AU  - Gea, F
AU  - Olveira, A
AU  - Fernandez-Carrillo, C
AU  - Polo, B
AU  - Carrión, J A
AU  - Gómez, A
AU  - Devesa, M J
AU  - Baliellas, C
AU  - Castro, Á
AU  - Ampuero, J
AU  - Granados, R
AU  - Pascasio, J M
AU  - Rubín, A
AU  - Salmeron, J
AU  - Badia, E
AU  - Planas, J M M
AU  - Lens, S
AU  - Turnes, J
AU  - Montero, J L
AU  - Buti, M
AU  - Esteban, R
AU  - Fernández-Rodríguez, C M
PY  - 2016
DO  - 10.1111/jvh.12648
UR  - http://hdl.handle.net/10668/10667
T2  - Journal of viral hepatitis
AB  - Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical...
LA  - en
KW  - SVR12
KW  - cirrhosis
KW  - daclatasvir
KW  - genotype 3
KW  - hepatitis C
KW  - ledipasvir
KW  - observational study
KW  - real-world cohort
KW  - sofosbuvir
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antiviral Agents
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - Hepatitis C, Chronic
KW  - Humans
KW  - Liver Cirrhosis
KW  - Male
KW  - Middle Aged
KW  - Ribavirin
KW  - Sofosbuvir
KW  - Treatment Outcome
KW  - Viral Nonstructural Proteins
KW  - Young Adult
TI  - Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
TY  - research article
VL  - 24
ER  -